|
Market Closed -
Nasdaq
16:00:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 803.48 USD | -0.31% |
|
+2.44% | +4.10% |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66,029 | 77,057 | 93,403 | 76,639 | 79,193 | 80,231 | - | - |
| Change | - | 16.7% | 21.21% | -17.95% | 3.33% | 1.31% | - | - |
| Enterprise Value (EV) 1 | 56,196 | 77,057 | 84,542 | 70,331 | 73,294 | 73,363 | 69,678 | 66,199 |
| Change | - | 37.12% | 9.71% | -16.81% | 4.21% | 0.09% | -5.02% | -4.99% |
| P/E | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 18.6x | 15.9x | 14.1x |
| PBR | 3.56x | 3.41x | 3.64x | 2.62x | 2.58x | 2.45x | 2.07x | 1.82x |
| PEG | - | -0.4x | -2.8x | 1.8x | 2.27x | 4.54x | 1x | 1.1x |
| Capitalization / Revenue | 4.11x | 6.33x | 7.12x | 5.4x | 5.52x | 4.74x | 4.37x | 4.09x |
| EV / Revenue | 3.5x | 6.33x | 6.45x | 4.95x | 5.11x | 4.33x | 3.8x | 3.38x |
| EV / EBITDA | 5.71x | 12.7x | 15.2x | 12.3x | 13.5x | 10.2x | 9.45x | 8.14x |
| EV / EBIT | 6.28x | 13.5x | 16.5x | 13.5x | 15x | 12x | 9.87x | 8.38x |
| EV / FCF | 8.61x | 17.4x | 21.8x | 19.2x | 18x | 12.4x | 10.8x | 9.33x |
| FCF Yield | 11.6% | 5.74% | 4.58% | 5.21% | 5.57% | 8.08% | 9.23% | 10.7% |
| Dividend per Share 2 | - | - | - | - | 3.52 | 3.902 | 4.438 | 5.005 |
| Rate of return | - | - | - | - | 0.46% | 0.49% | 0.55% | 0.62% |
| EPS 2 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 43.18 | 50.38 | 56.93 |
| Distribution rate | - | - | - | - | 8.49% | 9.04% | 8.81% | 8.79% |
| Net sales 1 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | 16,924 | 18,343 | 19,597 |
| EBITDA 1 | 9,835 | 6,060 | 5,547 | 5,695 | 5,428 | 7,184 | 7,376 | 8,135 |
| EBIT 1 | 8,947 | 5,719 | 5,126 | 5,212 | 4,884 | 6,104 | 7,063 | 7,904 |
| Net income 1 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | 4,695 | 5,348 | 6,019 |
| Net Debt 1 | -9,833 | - | -8,862 | -6,308 | -5,899 | -6,868 | -10,554 | -14,032 |
| Reference price 2 | 631.52 | 721.49 | 878.29 | 712.33 | 771.87 | 803.48 | 803.48 | 803.48 |
| Nbr of stocks (in thousands) | 104,556 | 106,802 | 106,347 | 107,590 | 102,599 | 99,855 | - | - |
| Announcement Date | 2/4/22 | 2/3/23 | 2/2/24 | 2/4/25 | 1/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.61x | 4.33x | 10.21x | 0.49% | 80.23B | |
| 37.7x | 12.88x | 24.51x | -.--% | 50.64B | |
| 21.26x | 4.7x | 13.43x | 0.69% | 46.87B | |
| -51.83x | 3.58x | 10.59x | 2.95% | 46.34B | |
| 37.28x | 3.45x | 13.12x | -.--% | 31B | |
| -7.38x | 10.27x | -6.63x | -.--% | 25.28B | |
| 52.93x | 3.38x | 26.22x | -.--% | 24.36B | |
| 69.87x | 6.7x | 44.75x | -.--% | 20.81B | |
| 23.08x | 4.97x | 12.94x | -.--% | 16.08B | |
| -29.07x | 16.49x | -43.97x | -.--% | 15.61B | |
| Average | 17.25x | 7.07x | 10.52x | 0.41% | 35.72B | |
| Weighted average by Cap. | 15.75x | 6.47x | 12.63x | 0.58% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- REGN Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
